Angiogenesis inhibitors for the treatment of hepatocellular carcinoma

Frontiers in Pharmacology

Volumn 7, Issue NOV, 2016, Pages

  Berretta, Massimiliano ^a   Rinaldi, Luca ^b   Di Benedetto, Fabrizio ^c   Lleshi, Arben ^a   Re, Vallì De ^a   Facchini, Gaetano ^d   De Paoli, Paolo ^a   Di Francia, Raffaele ^d  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Hepatocellular carcinoma; Inhibitors and toxicity; Neo angiogenesis; Pharmacogenomics; Target therapy; Treatment

Indexed keywords

BEVACIZUMAB; BRIVANIB; CABOZANTINIB; CEDIRANIB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; LENVATINIB; LINIFANIB; NINTEDANIB; RAMUCIRUMAB; REFAMETINIB; REGORAFENIB; SORAFENIB; TREBANANIB; VATALANIB;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CAUSE OF DEATH; CHEMOEMBOLIZATION; CHILD PUGH SCORE; COHORT ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; HYPERTENSION; IN VIVO STUDY; INTENTION TO TREAT ANALYSIS; LIVER CELL CARCINOMA; MULTICENTER STUDY (TOPIC); OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 85003904900     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2016.00428     Document Type: Review

References (99)

1. Abou-Alfa, G. K., Blanc, J. F., Miles, S., Ganten, T. M., Trojan, J., Cebon, J. S., et al. (2014). Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma (HCC) [Abstract]. J. Clin. Oncol. 32(Suppl. 3), 286.
2. Albert, D. H., Tapang, P., Magoc, T. J., Pease, L. J., Reuter, D. R., Wei, R. Q., et al. (2006). Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 5, 995-1006. doi: 10.1158/1535-7163.MCT-05-0410
3. Alberts, S. R., Fitch, T. R., Kim, G. P., Morlan, B. W., Dakhil, S. R., Gross, H. M., et al. (2012). Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II north central cancer treatment group clinical trial. Am. J. Clin. Oncol. 35, 329-333. doi: 10.1097/COC.0b013e3182118cdf
4. Bai, W., Wang, Y. J., Zhao, Y., Qi, X. S., Yin, Z. X., He, C. Y., et al. (2013). Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. J. Dig. Dis. 14, 181-190. doi: 10.1111/1751-2980.12038
5. Berretta, M., Di Benedetto, F., Di Francia, R., Lo Menzo, E., Palmeri, S., Tirelli, U., et al. (2013). Colorectal cancer in elderly patients: from best supportive care to cure. Anticancer Agents Med. Chem. 13, 1332-1343. doi: 10.2174/18715206113136660350
6. Berretta, M., Di Francia, R., Di Benedetto, F., and Tirelli, U. (2015a). New entities in the treatment of hepatocellular carcinoma: HIV-positive and elderly patients. WCRJ 2, e558.
7. Berretta, M., Di Francia, R., and Tirelli, U. (2014). Editorial-The new oncologic challenges in the 3rd millennium. WCRJ 1, e133
8. Berretta, M., Di Francia, R., and Tirelli, U. (2015b). Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma. Eur. Rev. Med. Pharmacol. Sci. 19, 2521-2522.
9. Berretta, M., Garlassi, E., Cacopardo, B., Cappellani, A., Guaraldi, G., Cocchi, S., et al. (2011). Hepatocellular carcinoma in HIV-infected patients: check early, treat hard. Oncologist16, 1258-1269. doi: 10.1634/theoncologist.2010-0400
10. Berretta, M., Martellotta, F., Di Francia, R., Spina, M., Vaccher, E., Balestreri, L., et al. (2015c). Clinical presentation and outcome of non-AIDS defining cancer, in HIV-infected patients in the ART-era:the Italian Cooperative Group on AIDS and tumors activity. Eur. Rev. Med. Pharmacol. Sci. 19, 3619-3634.
11. Berretta, S., Fisichella, R., Spartà, D., Lleshi, A., and Nasti, G. (2015). Primary liver cancer: clinical aspects, prognostic factors and predictive response to therapy. WCRJ 2:e561.
12. Boige, V., Malka, D., Bourredjem, A., Dromain, C., Baey, C., Jacques, N., et al. (2012). Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist 17, 1063-1072. doi: 10.1634/theoncologist.2011-0465
13. Bruix, J., Gores, G. J., and Mazzaferro, V. (2014a). Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 63, 844-855. doi: 10.1136/gutjnl-2013-306627
14. Bruix, J., Takayama, T., Mazzaferro, V., Chau, G.-Y., Yang, J., Kudo, M., et al. (2014b). STORM Investigators. STORM: a phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC) [Abstract]. J. Clin. Oncol. 32(5s Suppl.):4006.
15. Bruix, J., Tak, W. Y., Gasbarrini, A., Santoro, A., Colombo, M., Lim, H. Y., et al. (2013). Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur. J. Cancer49, 3412-3419. doi: 10.1016/j.ejca.2013.05.028
16. Buijs, M., Reyes, D. K., Pawlik, T. M., Blackford, A. L., Salem, R., Messersmith, W. A., et al. (2013). Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer 119, 1042-1049. doi: 10.1002/cncr.27859
17. Cai, Z. W., Zhang, Y., Borzilleri, R. M., Qian, L., Barbosa, S., Wei, D., et al. (2008). Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo(2, 1-f)(1, 2, 4)triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J. Med. Chem. 51, 1976-1980. doi: 10.1021/jm7013309
18. Cainap, C., Qin, S., Huang, W. T., Chung, I. J., Pan, H., Cheng, Y., et al. (2015). Linifanib Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 33, 172-179. doi: 10.1200/JCO.2013.54.3298
19. Canzonieri, V., Alessandrini, L., Caggiari, L., Perin, T., Berretta, M., Cannizzaro, R., et al. (2015). Hepatocellular carcinoma: an overvierw of clinic-pathological and molecular prespectives. WCRJ 2:e485.
20. Cervello, M., Bacharov, D., Lampiasi, N., Cusimano, A., Azzolina, A., McCubrey, J. A., et al. (2012). Molecular mechanisms of sorafenib action in liver cancer cells. Cell Cycle 11, 2843-2855. doi: 10.4161/cc.21193
21. D'Amico, G., Tarantino, G., Ballarin, R., Serra, V., Pecchi, A. R., Guaraldi, G., et al. (2015a). Liver resection for HCC in HIV-infected patients: a single center experience. WCRJ 2:e490.
22. D'Amico, G., Tarantino, G., Serra, V., Ballarin, R., and Di Benedetto, F. (2015b). Isolated caudate lobectomy for Spiegel lobe neoplasms. WCRJ 2:e490.
23. Demetri, G. D., Reichardt, P., Kang, Y. K., Blay, J. Y., Rutkowski, P., Gelderblom, H., et al. (2013). GRID study investigators. GRID study investigators. Efficacy and safety of regorafenib for advanced gastroin inal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 295-302. doi: 10.1016/S0140-6736(12)61857-1
24. De Monaco, A., Faioli, D., Di Paolo, M., Catapano, O., D'Orta, A., Del Buono, M., et al. (2014). Pharmacogenomics markers for prediction response and toxicity in cancer therapy. WCRJ 1:e276.
25. Di Benedetto, F., Berretta, M., De Ruvo, N., Tarantino, G., D'Amico, G., Ballarin, R., et al. (2012). Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadiuvant approach plus m-TOR inhibitors monotherapy? J. Surg. Oncol. 105, 111-112. doi: 10.1002/jso.22039
26. Di Benedetto, F., De Ruvo, N., Berretta, M., Masetti, M., Montalti, R., Di Sandro, S., et al. (2008). Hepatocellular carcinoma in HIV patients treated by liver transplsntation. Eur. J. Surg. Oncol. 34, 422-427. doi: 10.1016/j.ejso.2007.05.004
27. Di Benedetto, F., Tarantino, G., Ercolani, G., Baccarani, U., Montalti, R., De Ruvo, N., et al. (2013b). Multicenter Italian experience in liver transplantation for hepatocellular carcinoma in HIV-infected patients. Oncologist 18, 592-599. doi: 10.1634/theoncologist.2012-0255
28. Di Benedetto, F., Tarantino, G., Montalti, R., Ballarin, R., D'Amico, G., Berretta, M., et al. (2011). Sorafenib before liver transplantation for hepatocellular carcinoma: risk or give up. Transpl. Int. 24:e97. doi: 10.1111/j.1432-2277.2011.01329.x
29. Di Benedetto, F., Tarantino, G., Quintini, C., Tirelli, U., and Berretta, M. (2013a). Hepatocellular carcinoma: beyond the boundaries of age. Anticancer Agents Med. Chem. 13, 1371-1377. doi: 10.2174/18715206113136660342
30. Ellingson, B. M., Kim, H. J., Woodworth, D. C., Pope, W. B., Cloughesy, J. N., Harris, R. J., et al. (2014). Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology 271, 200-210. doi: 10.1148/radiol.13131305
31. Falchook, G. S., Naing, A., Hong, D. S., Zinner, R., Fu, S., Piha-Paul, S. A., et al. (2013). Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. Oncotarget 4, 118-127. doi: 10.18632/oncotarget.763
32. Ferrara, N., Gerber, H. P., and LeCouter, J. (2003). The biology of VEGF and its receptors. Nat. Med. 9, 669-676. doi: 10.1038/nm0603-669
33. Finn, R. S., Kang, Y. K., Mulcahy, M., Polite, B. N., Lim, H. Y., Walters, I., et al. (2012). Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 18, 2090-2098. doi: 10.1158/1078-0432.CCR-11-1991
34. Finn, R. S., Poon, R. T., Yau, T., Klümpen, H. J., Chen, L. T., Kang, Y. K., et al. (2013). Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. J. Hepatol. 59, 1271-1277. doi: 10.1016/j.jhep.2013.07.029
35. Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., et al. (2014). REGARD trial investigators. REGARD trial investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomized, multicentre, placebo-controlled, phase 3 trial. Lancet 383, 31-39. doi: 10.1016/S0140-6736(13)61719-5
36. Garbuzenko, D. V., Arefyev, N. O., and Belov, D. V. (2016). Mechanisms of adaptation of the hepatic vasculature to the deteriorating conditions of blood circulation in liver cirrhosis. World J. Hepatol. 8, 665-672. doi: 10.4254/wjh.v8.i16.665
37. Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., et al. (2008). BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 68, 4774-4782. doi: 10.1158/0008-5472.CAN-07-6307
38. Hirotsu, Y., Zheng, T.-H., Amemiya, K., Mochizuki, H., Guleng, B., and Omata, M. (2016). Targeted and exome sequencing identified somatic mutations in hepatocellular carcinoma. Hepatol. Res. 46, 1145-1151. doi: 10.1111/hepr.12663
39. Hong, K., Khwaja, A., Liapi, E., Torbenson, M. S., Georgiades, C. S., and Geschwind, J. F. (2006). New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin. Cancer Res. 12, 2563-2567. doi: 10.1158/1078-0432.CCR-05-2225
40. Hsu, C. H., Yang, T. S., Hsu, C., Toh, H. C., Epstein, R. J., Hsiao, L. T., et al. (2010). Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br. J. Cancer 102, 981-986. doi: 10.1038/sj.bjc.6605580
41. Huynh, H., Ngo, V. C., Fargnoli, J., Ayers, M., Soo, K. C., Koong, H. N., et al. (2008). Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin. Cancer Res. 14, 6146-6153. doi: 10.1158/1078-0432.CCR-08-0509
42. Iverson, C., Larson, G., Lai, C., Yeh, L. T., Dadson, C., Weingarten, P., et al. (2009). REDA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK 1/2 for the treatment of cancer. Cancer Res. 69, 6839-6847. doi: 10.1158/0008-5472.CAN-09-0679
43. Johnson, P. J., Qin, S., Park, J. W., Poon, R. T., Raoul, J. L., Philip, P. A., et al. (2013). Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J. Clin. Oncol. 31, 3517-3524. doi: 10.1200/JCO.2012.48.4410
44. Kim, M. N., Kim, B. K., Han, K. H., and Kim, S. U. (2015). Evolution from WHO to EASL and RECIST for hepatocellular carcinoma: considerations for tumor response assessment. Expert Rev. Gastroenterol. Hepatol. 9, 335-348. doi: 10.1586/17474124.2015.959929
45. Koch, S., Tugues, S., Li, X., Gualandi, L., and Claesson-Welsh, L. (2011). Signal transduction by vascular endothelial growth factor receptors. Biochem. J. 437, 169-183. doi: 10.1042/BJ20110301
46. Korpanty, G., and Smyth, E. (2012). Anti-VEGF strategies-from antibodies to tyrosine kinase inhibitors: background and clinical development in human cancer. Curr. Pharm. Des. 18, 2680-2701. doi: 10.2174/138161212800626166
47. Kubo, N., Araki, K., Kuwano, H., and Shirabe, K. (2016). Cancer-associated fibroblasts in hepatocellular carcinoma. World J. Gastroenterol. 22, 6841-6850. doi: 10.3748/wjg.v22.i30.6841
48. Kudo, K., Arao, T., Tanaka, K., Nagai, T., Furuta, K., Sakai, K., et al. (2011). Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo. Clin. Cancer Res. 17, 1373-1381. doi: 10.1158/1078-0432.CCR-09-2755
49. Lammer, J., Malagari, K., Vogl, T., Pilleul, F., Denys, A., Watkinson, A., et al. (2010). Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc. Intervent. Radiol. 33, 41-52. doi: 10.1007/s00270-009-9711-7
50. Lim, H. Y., Heo, J., Choi, H. J., Lin, C. Y., Yoon, J. H., Hsu, C., et al. (2014). A phase II study of the efficacy and safety of the combination therapy of MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. Clin. Cancer Res. 20, 5976-5985. doi: 10.1158/1078-0432.CCR-13-3445
51. Llovet, J. M. (2014). Liver cancer: time to evolve trial desi gn after everolimus failure. Nat. Rev. Clin. Oncol. 11, 506-507. doi: 10.1038/nrclinonc.2014.136
52. Llovet, J. M., Burroughs, A., and Bruix, J. (2003). Hepatocellular carcinoma. Lancet 362, 1907-1917. doi: 10.1016/S0140-6736(03)14964-1
53. Llovet, J. M., Decaens, T., Raoul, J. L., Boucher, E., Kudo, M., Chang, C., et al. (2013). Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J. Clin. Oncol. 31, 3509-3516. doi: 10.1200/JCO.2012.47.3009
54. Llovet, J. M., and Hernandez-Gea, V. (2014). Hepatocellular carcinoma: reasons for phase 3 failure and novel perspectives on trial design. Clin. Cancer Res. 20, 2072-2079. doi: 10.1158/1078-0432.CCR-13-0547
55. Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., et al. (2008). SHARP investigators study group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390. doi: 10.1056/NEJMoa0708857
56. Lo, C. M., Ngan, H., Tso, W. K., Liu, C. L., Lam, C. M., Poon, R. T., et al. (2002). Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35, 1164-1171. doi: 10.1053/jhep.2002.33156
57. Mazzaferro, V., Lencioni, R., and Majno, P. (2014). Early hepatocellular carcinoma on the procrustean bed of ablation, resection, and transplantation. Semin. Liver Dis. 34, 415-426. doi: 10.1055/s-0034-1394365
58. Monk, B. J., Poveda, A., Vergote, I., Raspagliesi, F., Fujiwara, K., Bae, D. S., et al. (2014). Anti-angioprotein therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomized, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 15, 799-808. doi: 10.1016/S1470-2045(14)70244-X
59. Murakami, M., Kobayashi, S., Marubashi, S., Tomimaru, Y., Noda, T., Wada, H., et al. (2011). Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-a/5-fluorouracil therapy for hepatocellular carcinoma cells. Ann. Surg. Oncol. 18, 589-596. doi: 10.1245/s10434-010-1310-y
60. Nunnari, G., Berretta, M., Pinzone, M. R., Di Rosa, M., Berretta, S., Cunsolo, G., et al. (2012). Hepatocellular carcinoma in HIV positive patients. Eur. Rev. Med. Pharmacol. Sci. 16, 1257-1270.
61. Park, J. W., Finn, R. S., Kim, J. S., Karwal, M., Li, R. K., Ismail, F., et al. (2011). Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 17, 1973-1983. doi: 10.1158/1078-0432.CCR-10-2011
62. Pawlik, T. M., Reyes, D. K., Cosgrove, D., Kamel, I. R., Bhagat, N., and Geschwind, J. F. (2011). Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J. Clin. Oncol. 29, 3960-3967. doi: 10.1200/JCO.2011.37.1021
63. Piguet, A. C., Saar, B., Hlushchuk, R., St-Pierre, M. V., McSheehy, P. M., Radojevic, V., et al. (2011). Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Mol. Cancer Ther. 10, 1007-1017. doi: 10.1158/1535-7163.MCT-10-0666
64. Reyes, D. K., Vossen, J. A., Kamel, I. R., Azad, N. S., Wahlin, T. A., Torbenson, M. S., et al. (2009). Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J. 15, 526-532. doi: 10.1097/PPO.0b013e3181c5214b
65. Risau, W. (1997). Mechanisms of angiogenesis. Nature 386, 671-674. doi: 10.1038/386671a0
66. Roberts, P. J., and Der, C. J. (2007). Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26, 3291-3310. doi: 10.1038/sj.onc.1210422
67. Roy, S., Narang, B. K., Rastogi, S. K., and Rawal, R. K. (2015). A novel multiple tyrosine-kinase targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple solid tumors: cabozantinib. Anticancer Agents Med. Chem. 15, 37-47. doi: 10.2174/1871520614666140902153840
68. Santoro, A., Rimassa, L., Borbath, I., Daniele, B., Salvagni, S., Van Laethem, J. L., et al. (2013). Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebocontrolled phase 2 study. Lancet Oncol. 14, 55-63. doi: 10.1016/S1470-2045(12)70490-4
69. Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., et al. (2015). Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372, 621-630. doi: 10.1056/NEJMoa1406470
70. Schmieder, R., Puehler, F., Neuhaus, R., Kissel, M., Adjei, A. A., Miner, J. N., et al. (2013). Allosteric MEK l/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits anti tumor activity in preclinical murine and rat models of hepatocellular carcinoma. Neoplasia 15, 1161-1171. doi: 10.1593/neo.13812
71. Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., and Dvorak, H. F. (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983-985.
72. Shibuya, M., and Claesson-Welsh, L. (2006). Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp. Cell Res. 312, 549-560. doi: 10.1016/j.yexcr.2005.11.012
73. Strumberg, D., and Schultheis, B. (2012). Regorafenib for cancer. Expert Opin. Investig. Drugs 21, 879-889. doi: 10.1517/13543784.2012.684752
74. Sun, W., Sohal, D., Haller, D. G., Mykulowycz, K., Rosen, M., Soulen, M. C., et al. (2011). Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer 117, 3187-3192. doi: 10.1002/cncr.25889
75. Tai, W. T., Shiau, C. W., Li, Y. S., Chang, C. W., Huang, J. W., Hsueh, T. T., et al. (2014). Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity. J. Hepatol. 61, 89-97. doi: 10.1016/j.jhep.2014.03.017
76. Thomas, K. A. (1996). Vascular endothelial grouth factor, a potent and selective angiogenic agents. J. Biol. Chem. 271, 603-606.
77. Thomas, M. B., Morris, J. S., Chadha, R., Iwasaki, M., Kaur, H., Lin, E., et al. (2009). Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J. Clin. Oncol. 27, 843-850. doi: 10.1200/JCO.2008.18.3301
78. Toh, H. C., Chen, P. J., Carr, B. I., Knox, J. J., Gill, S., Ansell, P., et al. (2013). Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer 119, 380-387. doi: 10.1002/cncr.27758
79. Ursino, S., Greco, C., Cartei, F., Colosimo, C., Stefanelli, A., Caccopardo, B., et al. (2012). Radiotherapy and hepatocellular carcinoma: update and review of literature. Eur. Rev. Med. Pharmacol. Sci. 16, 1599-1604.
80. Varela, M., Real, M. I., Burrel, M., Forner, A., Sala, M., Brunet, M., et al. (2007). Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J. Hepatol. 46, 474-481. doi: 10.1016/j.jhep.2006.10.020
81. Veikkola, T., Karkkainen, M., Claesson-Weish, L., and Alitalo, K. (2000). Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 60, 203-212.
82. Verslype, C., Cohn, A. L., Kelley, R. K., Yang, T. S., Su, W. C., Ramies, D. A., et al. (2012). Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT) [Abstract]. J. Clin. Oncol. 30(Suppl.):4007.
83. Wang, H., and Hartnett, M. E. (2016). Regulation of signaling events involved in the pathophysiology of neovascular AMD. Mol. Vis. 22, 189-202.
84. Wilke, H., Muro, K., Van Cutsem, E., Oh, S. C., Bodoky, G., Shimada, Y., et al. (2014). RAINBOW Study Group. RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomized phase 3 trial. Lancet Oncol. 15, 1224-1235. doi: 10.1016/S1470-2045(14)70420-6
85. Wood, J. M., Bold, G., Buchdunger, E., Cozens, R., Ferrari, S., Frei, J., et al. (2000). PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 60, 2178-2189.
86. Xiang, Q., Chen, W., Ren, M., Wang, J., Zhang, H., Deng, D. Y., et al. (2014). Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clin. Cancer Res. 20, 2959-2970. doi: 10.1158/1078-0432.CCR-13-2620
87. Yau, T., Chan, P., Pang, R., Ng, K., Fan, S. T., and Poon, R. T. (2010). Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma. Cancer 116, 5022-5029. doi: 10.1002/cncr.25372
88. Yi, Z. Y., Feng, L. J., Xiang, Z., and Yao, H. (2011). Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in hepatocellular carcinoma cells. J. Invest. Surg. 24, 67-76. doi: 10.3109/08941939.2010.542272
89. Yoshiji, H., Kuriyama, S., Yoshii, J., Ikenaka, Y., Noguchi, R., Yanase, K., et al. (2004). Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development. J. Hepatol. 41, 97-103. doi: 10.1016/j.jhep.2004.03.001
90. Zampino, R., Pisaturo, M. A., Cirillo, G., Marrone, A., Macera, M., Rinaldi, L., et al. (2015). Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration. Ann. Hepatol. 14, 75-82.
91. Zhao, Y., Wang, W. J., Guan, S., Li, H. L., Xu, R. C., Wu, J. B., et al. (2013). Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. Ann. Oncol. 24, 1786-1792. doi: 10.1093/annonc/mdt072
92. Zhu, A. X. (2006). Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 11, 790-800. doi: 10.1634/theoncologist.11-7-790
93. Zhu, A. X., Ancukiewicz, M., Supko, J. G., Sahani, D. V., Blaszkowsky, L. S., Meyerhardt, J. A., et al. (2013a). Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin. Cancer Res. 19, 1557-1566. doi: 10.1158/1078-0432.CCR-12-3041
94. Zhu, A. X., Blaszkowsky, L. S., Ryan, D. P., Clark, J. W., Muzikansky, A., Horgan, K., et al. (2006). Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24, 1898-1903. doi: 10.1200/JCO.2005.04.9130
95. Zhu, A. X., Duda, D. G., Sahani, D. V., and Jain, R. K. (2011). HCC and angiogenesis: possible targets and future directions. Nat. Rev. Clin. Oncol. 8, 292-301. doi: 10.1038/nrclinonc.2011.30
96. Zhu, A. X., Finn, R. S., Mulcahy, M., Gurtler, J., Sun, W., Schwartz, J. D., et al. (2013b). A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin. Cancer Res. 19, 6614-6623. doi: 10.1158/1078-0432.CCR-13-1442
97. Zhu, A. X., Kudo, M., Assenat, E., Caltan, S., Kang, Y. K., Lim, Y., et al. (2014a). EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib [Abstract]. J. Clin. Oncol. 32(Suppl. 3):172.
98. Zhu, A. X., Kudo, M., Assenat, E., Cattan, S., Kang, Y. K., Lim, H. Y., et al. (2014b). Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 312, 57-67. doi: 10.1001/jama.2014.7189
99. Zhu, A. X., Ryoo, B.-Y., Yen, C.-J., Kudo, M., Poon, R. T.-P., Pastorelli, D., et al. (2015). Ramucirumab (RAM) a second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): analysis of patients with elevated a-fetoprotein (AFP) from the randomized phase III REACH study [abstract]. J. Clin. Oncol. 33(Suppl. 3):232.